Literature DB >> 20529162

Destination therapy: patient selection and current outcomes.

Katherine Lietz1.   

Abstract

Long-term left-ventricular assist device (LVAD) support as destination therapy (DT) is a promising new alternative for the growing population of patients with advanced heart failure. In this article, we summarize the clinical trials that led to the approval of LVAD use as DT in the US national policies regulating candidate selection and DT center accreditation. We review current guidelines for candidate selection, clinical tools to assess candidate operative risk, and outcomes of DT.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20529162     DOI: 10.1111/j.1540-8191.2010.01050.x

Source DB:  PubMed          Journal:  J Card Surg        ISSN: 0886-0440            Impact factor:   1.620


  13 in total

1.  Reduced handgrip strength as a marker of frailty predicts clinical outcomes in patients with heart failure undergoing ventricular assist device placement.

Authors:  Christine J Chung; Christina Wu; Meaghan Jones; Tomoko S Kato; Tien T Dam; Raymond C Givens; Danielle L Templeton; Mathew S Maurer; Yoshifumi Naka; Hiroo Takayama; Donna M Mancini; P Christian Schulze
Journal:  J Card Fail       Date:  2014-02-22       Impact factor: 5.712

Review 2.  A ventricular assist device as a bridge to recovery, decision making, or transplantation in patients with advanced cardiac failure.

Authors:  Siyamek Neragi-Miandoab
Journal:  Surg Today       Date:  2012-07-20       Impact factor: 2.549

3.  Mechanistic insight of platelet apoptosis leading to non-surgical bleeding among heart failure patients supported by continuous-flow left ventricular assist devices.

Authors:  Nandan K Mondal; Tieluo Li; Zengsheng Chen; Hegang H Chen; Erik N Sorensen; Si M Pham; Michael A Sobieski; Steven C Koenig; Mark S Slaughter; Bartley P Griffith; Zhongjun J Wu
Journal:  Mol Cell Biochem       Date:  2017-03-25       Impact factor: 3.396

4.  Oxidative stress induced modulation of platelet integrin α2bβ3 expression and shedding may predict the risk of major bleeding in heart failure patients supported by continuous flow left ventricular assist devices.

Authors:  Nandan K Mondal; Zengsheng Chen; Jaimin R Trivedi; Erik N Sorensen; Si M Pham; Mark S Slaughter; Bartley P Griffith; Zhongjun J Wu
Journal:  Thromb Res       Date:  2017-09-08       Impact factor: 3.944

5.  Comparison of intraplatelet reactive oxygen species, mitochondrial damage, and platelet apoptosis after implantation of three continuous flow left ventricular assist devices: HeartMate II, Jarvik 2000, and HeartWare.

Authors:  Nandan K Mondal; Erik N Sorensen; Erika D Feller; Si M Pham; Bartley P Griffith; Zhongjun J Wu
Journal:  ASAIO J       Date:  2015 May-Jun       Impact factor: 2.872

Review 6.  Frailty and the selection of patients for destination therapy left ventricular assist device.

Authors:  Kelsey M Flint; Daniel D Matlock; Joann Lindenfeld; Larry A Allen
Journal:  Circ Heart Fail       Date:  2012-03-01       Impact factor: 8.790

7.  Platelet glycoprotein Ibα ectodomain shedding and non-surgical bleeding in heart failure patients supported by continuous-flow left ventricular assist devices.

Authors:  Jingping Hu; Nandan K Mondal; Erik N Sorensen; Ling Cai; Hong-Bin Fang; Bartley P Griffith; Zhongjun J Wu
Journal:  J Heart Lung Transplant       Date:  2013-09-19       Impact factor: 10.247

8.  Systemic Inflammatory Response Syndrome After Contentious-Flow Left Ventricular Assist Device Implantation and Change in Platelet Mitochondrial Membrane Potential.

Authors:  Nandan K Mondal; Erik N Sorensen; Erika D Feller; Si M Pham; Bartley P Griffith; Zhongjun J Wu
Journal:  J Card Fail       Date:  2015-04-25       Impact factor: 5.712

Review 9.  The practical role of echocardiography in selection, implantation, and management of patients requiring LVAD therapy.

Authors:  Maria Chiara Todaro; Bijoy K Khandheria; Timothy E Paterick; Matt M Umland; Vinay Thohan
Journal:  Curr Cardiol Rep       Date:  2014-04       Impact factor: 2.931

10.  Comparative efficacy of in vitro and in vivo metabolized aspirin in the DeBakey ventricular assist device.

Authors:  Jawaad Sheriff; Gaurav Girdhar; Wei-Che Chiu; Jolyon Jesty; Marvin J Slepian; Danny Bluestein
Journal:  J Thromb Thrombolysis       Date:  2014-05       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.